Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Hits New 52-Week High - Still a Buy?

Key Points

• Kiniksa shares reached a new 52-week high, trading as high as $83.78 and closing around $83.17, up 4.6%. The company has a $6.49 billion market capitalization and trades at a P/E ratio of 85.74.
• Analysts remain broadly positive, with eight Buy ratings and one Hold rating. The stock has a “Moderate Buy” consensus and an average price target of $93.14, including targets of $90 from Goldman Sachs and $107 from JPMorgan.
• Kiniksa reported quarterly earnings in line with expectations at $0.30 per share, while revenue of $243.6 million exceeded estimates. Its lead product is ARCALYST, an approved treatment for recurrent pericarditis and certain periodic fever syndromes.

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report)'s share price reached a new 52-week high during trading on Wednesday. The company traded as high as $83.78 and last traded at $83.17, with a volume of 1,235,582 shares traded. The stock had previously closed at $79.48.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on KNSA. Wells Fargo & Company started coverage on Kiniksa Pharmaceuticals International in a research report on Wednesday, September 30th. They set an "overweight" rating and a $87.00 price target on the stock. The Goldman Sachs Group raised their price objective on Kiniksa Pharmaceuticals International from $75.00 to $90.00 and gave the company a "buy" rating in a research report on Thursday, July 30th. Weiss Ratings upgraded Kiniksa Pharmaceuticals International from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Thursday, October 8th. Wall Street Zen downgraded Kiniksa Pharmaceuticals International from a "strong-buy" rating to a "buy" rating in a research note on Sunday, July 12th. Finally, JPMorgan Chase & Co. boosted their target price on Kiniksa Pharmaceuticals International from $72.00 to $107.00 and gave the stock an "overweight" rating in a report on Wednesday, July 29th. Eight analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $93.14.

Kiniksa Pharmaceuticals International Trading Up 4.6%

The stock has a market cap of $6.49 billion, a P/E ratio of 85.74 and a beta of 0.04. The firm has a 50-day simple moving average of $78.04 and a two-hundred day simple moving average of $64.54.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last posted its earnings results on Tuesday, July 28th. The company reported $0.30 earnings per share for the quarter, hitting analysts' consensus estimates of $0.30. The company had revenue of $243.60 million during the quarter, compared to the consensus estimate of $226.49 million. Kiniksa Pharmaceuticals International had a return on equity of 13.65% and a net margin of 9.59%. Sell-side analysts predict that Kiniksa Pharmaceuticals International, plc will post 1.37 earnings per share for the current year.

Insider Transactions at Kiniksa Pharmaceuticals International

In other news, Director G. Bradley Cole sold 3,673 shares of the firm's stock in a transaction that occurred on Wednesday, July 29th. The shares were sold at an average price of $81.43, for a total transaction of $299,092.39. Following the transaction, the director directly owned 11,672 shares of the company's stock, valued at approximately $950,450.96. This trade represents a 23.94% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CAO Michael R. Megna sold 4,600 shares of Kiniksa Pharmaceuticals International stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $80.30, for a total transaction of $369,380.00. Following the completion of the sale, the chief accounting officer owned 29,062 shares of the company's stock, valued at approximately $2,333,678.60. The trade was a 13.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 51.98% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

Institutional investors have recently made changes to their positions in the stock. Robeco Institutional Asset Management B.V. bought a new position in shares of Kiniksa Pharmaceuticals International in the third quarter worth $1,046,000. USA Financial Formulas acquired a new position in Kiniksa Pharmaceuticals International in the third quarter valued at about $69,000. TD Waterhouse Canada Inc. lifted its position in Kiniksa Pharmaceuticals International by 3.9% during the third quarter. TD Waterhouse Canada Inc. now owns 17,343 shares of the company's stock worth $1,304,000 after purchasing an additional 652 shares during the period. B. Riley Wealth Advisors Inc. bought a new stake in Kiniksa Pharmaceuticals International during the third quarter worth about $763,000. Finally, GAMMA Investing LLC lifted its position in Kiniksa Pharmaceuticals International by 21.1% during the third quarter. GAMMA Investing LLC now owns 1,278 shares of the company's stock worth $95,000 after purchasing an additional 223 shares during the period. 53.95% of the stock is currently owned by institutional investors.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International plc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for patients with serious and often under-treated immunological diseases. The company's research and development efforts are centered on targeting specific pathways involved in inflammation and immune-system dysfunction.

Kiniksa's principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor. In the United States, ARCALYST is approved for reducing the risk of recurrence in patients with recurrent pericarditis and for the treatment of cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome, in eligible patients.

The company also maintains a pipeline of investigational medicines designed to address autoimmune and inflammatory conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.